Eran Broshy

Track

Insider profile

Performance

Overall performance
1.7
Performance over holding periods
1.7
30 days 90 days 120 days
Average return -9% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
2 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Magellan Health Inc Feb. 1, 2009 - May 1, 2019
Eran Broshy's trades of Theravance Biopharma Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-01 2025-11-26
PlS Planned sale
2,585 -27.1%
53.06
US$2,043,513 		2,585 -27.1% 53.06 US$2,043,513
2025-12-01 2025-11-26
PlS Planned sale
91,025 -3.5%
430.37
US$2,651,688 		91,025 -3.5% 430.37 US$2,651,688
2025-11-26 2025-11-26
PrS Proposed sale
1,124
229.17
US$2,123,248 		1,124 229.17 US$2,123,248
2025-11-13 2025-11-11
PlS Planned sale
14,000 -23.3%
18.50
US$259,000 		14,000 -23.3% 18.50 US$259,000
2025-11-13 2025-11-11
PlS Planned sale
15,500 -25.1%
17.00
US$263,500 		15,500 -25.1% 17.00 US$263,500
2025-11-13 2025-11-11
PlS Planned sale
29,500 -32.3%
18.50
US$545,750 		29,500 -32.3% 18.50 US$545,750
2025-11-12 2025-11-11
PrS Proposed sale
45,000
17.98
US$809,250 		45,000 17.98 US$809,250
2023-08-23 2023-08-22
US Certara Inc (CERT)
B Purchase
4,807 +50.3%
15.80
US$75,951 		4,807 +50.3% 15.80 US$75,951
2023-08-23 2023-08-21
US Certara Inc (CERT)
B Purchase
193 +2.1%
16.10
US$3,107 		193 +2.1% 16.10 US$3,107
2004-10-20 2004-10-18
S Sale
75,000 -51.6%
17.56
US$1,316,888 		75,000 -51.6% 17.56 US$1,316,888
2004-10-05 2004-10-01
S Sale
50,000 -25.6%
16.99
US$849,420 		50,000 -25.6% 16.99 US$849,420